Bones is mia on the sce bb where he was holding the end is nigh placard at 0.2p .... |
Chart forming nicely.Next leg up in progress?Blue close? |
Now the hype has gone comes the placing news . Give it a month or two and watch this start to fall asleep it becomes clear that it's coming and they approach the city . Glad I sold out some time ago at a good profit . The facts are there for all to see and cash is a problem again here very soon
I see hazel hasn't learnt from last time when they announced the 1 5p placing and wouldn't listen . Ignoring the cash position here will only lead to investors losing money and until they approach break even that will continue to be the biggest issue . |
Faraway2 has provided a good post, as
directors know what is happening on the ground
AND what might be in the pipeline.
DYOR |
Completely misguiding post 887.
Director buys are often a very good sign. |
Anybody follow buy based on that is foolish. |
Five senior employees buying shares in the company is a significant vote of confidence for what lies ahead in 2025.They quite obviously do not want to miss out on the growth prospect resulting from the recent RNSd newsflow plus imminent developments on a number of fronts.Prosperous New Year! |
GDR Is doing extremely well and takes the opposite position in order to earn it's crust, compared to some people above.
It concentrates on making people's lives better, instead of worse.
Happy new year to genuine holders! |
GDR should have been smarter and invented a kit to detect/treat mental illness in this global depression. People are trying to survive and no one is having babies. |
Imagine having this man firmly on our side. |
No no no 99% of aim stocks are corrupt |
Many deluded posters on here thinking they'd get in at 0.5p
You can stick that in your pipe Tonto ... and smoke it
𝐓uesdays 𝐖ednesdays 𝐀nd 𝐓hursdays |
posted on the BOWL thread
GDR..
The weekly chart over a two year period looks excellent.
Current share price 2.5p is at the bottom of a forming bowl, I would expect this to get back to the 20p mark within months and then retest the highs of 2023, circa 42p |
Ah .
Hadn't looked in since thanks egg and nowenterprise. |
Hazl Link doesn’t seem to work! |
Don't forget we might well be read over the holiday by those of influence.
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that the clinical performance of its CYP2C19-ID Kit has been published in the Journal of Molecular Biology. The publication is available at |
Certainly feels more alive than it ever did, share price wise.
At last investors realise, perhaps, that we have something rather special and the important catalyst of the medical staff, headed by John McDermott firmly behind it. |
Institution nibbling?? |
The pharma side takes years of jumping through hoops as we know Dabeesg.
I understand you were being genuine but let's face it we are nearer than we have ever been, to these products being rolled out internationally, and bringing with it a better quality of life and outcome for those affected.
It is a very rewarding company to be associated with, doing nothing but good with it's products.
The enthusiasm from John Mcdermott is palpable! |
Why would the NHS fund this when they know newborn babies are on a gradual decline |
That DM report is dated 12 Feb 2019 |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
